Co-Authors
This is a "connection" page, showing publications co-authored by JING YANG and HAIYAN LI.
Connection Strength
0.904
-
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One. 2013; 8(12):e82453.
Score: 0.122
-
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012 Dec 15; 72(24):6393-402.
Score: 0.113
-
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012 Sep; 26(9):2114-23.
Score: 0.108
-
Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010 Jul 15; 116(2):210-7.
Score: 0.094
-
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009 Feb 01; 15(3):951-9.
Score: 0.087
-
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother. 2014 Aug; 63(8):835-45.
Score: 0.031
-
Anti-?2M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer. 2014 Sep 01; 135(5):1132-41.
Score: 0.031
-
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013 Sep; 98(9):1458-66.
Score: 0.029
-
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol. 2012 Nov; 170(2):167-77.
Score: 0.028
-
Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 2012 Nov; 122(11):4160-71.
Score: 0.028
-
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013 Mar; 27(3):702-10.
Score: 0.028
-
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92.
Score: 0.028
-
Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer. 2013 Feb 15; 119(4):782-91.
Score: 0.028
-
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl). 2012 Jun; 90(6):695-706.
Score: 0.027
-
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood. 2012 Jan 05; 119(1):161-9.
Score: 0.026
-
CpG or IFN-a are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother. 2012 Apr; 61(4):561-71.
Score: 0.026
-
Targeting cell surface ?2 -microglobulin by pentameric IgM antibodies. Br J Haematol. 2011 Jul; 154(1):111-21.
Score: 0.025
-
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009 Oct 22; 114(17):3625-8.
Score: 0.023
-
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 2008 Oct 15; 68(20):8456-64.
Score: 0.021